JPX · 4519.T
Chugai Pharmaceutical Co., Ltd.
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
Loading market information…
JPX · 4565.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Nxera Pharma Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nxera Pharma Co., Ltd.’s next earnings report is currently expected on Feb 16, 2027, with estimated earnings per share of ¥80. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nxera Pharma Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 8, 2025 |
| -¥26-247.96% vs estimate |
| ¥8.45B-17.16% vs estimate |
| Q1 2025 | May 2, 2025 | -¥8+78.94% vs estimate | ¥6.64B-16.43% vs estimate |
|---|
| Q4 2024 | Feb 11, 2025 | -¥15-118.14% vs estimate | ¥6.85B-61.13% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
¥2,754+¥137 (+5.21%)
Daiichi Sankyo Company, Limited’s quoted price sits in the lower half of its reported 52-week range, 30.19% below the high.
¥2,571+¥58 (+2.31%)
Astellas Pharma Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.37% below the high.
¥3,012+¥23 (+0.77%)
Shionogi & Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.85% below the high.
¥5,052+¥78 (+1.57%)
Eisai Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 3.64% below the high.
¥2,464+¥63 (+2.6%)
Kyowa Kirin Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 15.38% below the high.
¥2,256+¥32 (+1.42%)
Ono Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.65% below the high.
¥1,885-¥61 (-3.11%)
Sumitomo Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.69% below the high.
